Min Chan Kim

Min Chan Kim

Auto-generated profile, based on publicly available information

Min Chan Kim

Department of Surgery, College of Medicine, Dong-A University

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SLSuee Lee
Suee Lee
Sung Yong OhSung Yong Oh
Sung Yong Oh
SKSung Hyun Kim
Sung Hyun Kim
JLJi Hyun Lee
Ji Hyun Lee
MKMin Chan Kim
Min Chan Kim
HKHyo-Jin Kim
Hyo-Jin Kim
Background: Several inflammatory response materials could be used for prediction of prognosis of cancer patients. The neutrophil lymphocyte ratio (NLR), and the platelet lymphocyte ratio (PLR) have been introduced for prognostic scoring system in various cancers. The objective of this study was to determine whether the NLR or the PLR would predict the clinical outcomes in advanced gastric cancer patients treated with oxaliplatin/ 5-fluorouracil (FOLFOX).Methods: The study population consisted of 174 advanced gastric cancer patients. Patients were treated with 85 mg/m2of oxaliplatin as a 2-h infusion at day 1 plus 20 mg/m2of leucovorin over 10 min, followed by 5-FU bolus 400 mg/m2and 22-h continuous infusion of 600 mg/m2at days 1-2. Treatment was repeated in 2-week intervals. The NLR and PLR were calculated from complete blood counts in laboratory test before and after first cycle of chemotherapy.Results: NLR was a useful prognostic biomarker for predicting inferior overall survival (OS) (p= 0.005), but was not associated with progression free survival (PFS) (p= 0.461). The normalization of NLR after one cycle of chemotherapy was found to be in association with significant improvement in PFS (5.3 months vs. 2.4 months,p< 0.001), and OS (11.9 months vs. 4.6 months,p< 0.001). The normalization of PLR was also associated with longer PFS (5.6 months vs. 3.4 months,p= 0.006), and OS (16.9 months vs. 10.9 months,p= 0.002). In multivariate analysis, changes in NLR were associated with PFS (Hazard ratio (HR): 2.297, 95% confidence interval (CI): 1.429-3.693,p= 0.001). The NLR, (HR: 0.245, 95% CI: 0.092-0.633,p= 0.004), PLR (HR: 0.347, 95% CI: 0.142-0.847,p= 0.020), changes in NLR (HR: 2.468, 95% CI: 1.567-3.886,p< 0.001), and changes in PLR (HR: 1.473, 95% CI: 1.038-2.090,p= 0.030) were independent prognostic markers for OS.Conclusion: This study demonstrates that NLR, PLR, and changes in NLR or PLR are independent prognostic factor for OS in patients with advanced gastric cancer treated with chemotherapy. These specific factors may also help in identifying the patients, who are more sensitive to FOLFOX regimen.

18 August 2009 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
MKMin-Chan Kim
Min-Chan Kim
GHGeon-Ung Heo
Geon-Ung Heo
GJGhap-Joong Jung
Ghap-Joong Jung

20 May 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DKDo-Kyong Kim
Do-Kyong Kim
SOSung Yong Oh
Sung Yong Oh
HKHyuk-Chan Kwon
Hyuk-Chan Kwon
SLSuee Lee
Suee Lee
KKKyung A Kwon
Kyung A Kwon
HKHyo-Jin Kim
Hyo-Jin Kim
The interleukin-6 (IL-6) pathway is one of the mechanisms that link inflammation and angiogenesis to malignancy. Because the C-reactive protein (CRP) is a representative marker for inflammation, CRP has recently been associated with the progression of disease in many cancer types. The principal objective of this study was to determine the preoperative serum levels of IL-6 and CRP in gastric carcinoma, and to correlate them with disease status and prognosis.

5 May 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HHHoon Hur
Hoon Hur
HLHyun Yong Lee
Hyun Yong Lee
HLHyuk-Joon Lee
Hyuk-Joon Lee
MKMin Chan Kim
Min Chan Kim
WHWoo Jin Hyung
Woo Jin Hyung
SHSang-Uk Han
Sang-Uk Han
Despite the well-described benefits of laparoscopic surgery such as lower operative blood loss and enhanced postoperative recovery in gastric cancer surgery, the application of laparoscopic surgery in patients with locally advanced gastric cancer (AGC) remains elusive owing to a lack of clinical evidence. Recently, the Korean Laparoscopic Surgical Society Group launched a new multicenter randomized clinical trial (RCT) to compare laparoscopic and open D2 lymphadenectomy for patients with locally AGC. Here, we introduce the protocol of this clinical trial. This trial is an investigator-initiated, randomized, controlled, parallel group, non-inferiority trial. Gastric cancer patients diagnosed with primary tumors that have invaded into the muscle propria and not into an adjacent organ (cT2–cT4a) in preoperative studies are recruited. Another criterion for recruitment is no lymph node metastasis or limited perigastric lymph node (including lymph nodes around the left gastric artery) metastasis. A total 1,050 patients in both groups are required to statistically show non-inferiority of the laparoscopic approach with respect to the primary end-point, relapse-free survival of 3 years. Secondary outcomes include postoperative morbidity and mortality, postoperative recovery, quality of life, and overall survival. Surgeons who are validated through peer-review of their surgery videos can participate in this clinical trial. This clinical trial was designed to maintain the principles of a surgical clinical trial with internal validity for participating surgeons. Through the KLASS-02 RCT, we hope to show the efficacy of laparoscopic D2 lymphadenectomy in AGC patients compared with the open procedure. ClinicalTrial.gov, NCT01456598 .

19 March 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HKHyoungil Kim
Hyoungil Kim
HHHoon Hur
Hoon Hur
YKYoun Nam Kim
Youn Nam Kim
HLHyuk-Joon Lee
Hyuk-Joon Lee
MKMin-Chan Kim
Min-Chan Kim
WHWoo Jin Hyung
Woo Jin Hyung
Extended systemic lymphadenectomy (D2) is standard procedure for surgical treatment of advanced gastric cancer (AGC) although less extensive lymphadenectomy (D1) can be applied to early gastric cancer. Complete D2 lymphadenectomy is the mandatory procedure for studies that evaluate surgical treatment results of AGC. However, the actual extent of D2 lymphadenectomy varies among surgeons because of a lacking consensus on the anatomical definition of each lymph node station. This study is aimed to develop a consensus for D2 lymphadenectomy and also to qualify surgeons that can perform both laparoscopic and open D2 gastrectomy.

1 May 2008 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SOSung Yong Oh
Sung Yong Oh
HKHyuk-Chan Kwon
Hyuk-Chan Kwon
SKSung-Hyun Kim
Sung-Hyun Kim
JJJin Seok Jang
Jin Seok Jang
MKMin Chan Kim
Min Chan Kim
HKHyo-Jin Kim
Hyo-Jin Kim
Background: Hypoxia influences tumor growth by inducing angiogenesis and genetic alterations. Hypoxia-inducible factor 1α (HIF-1α), p53, and vascular endothelial growth factor (VEGF) are all important factors in the mechanisms inherent to tumor progression. In this work, we have investigated the clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF (sVEGF) level in gastric cancer. We immunohistochemically assessed the HIF-1α, p53, and VEGF expression patterns in 114 specimens of gastric cancer. Additionally, we determined the levels of preoperative serum VEGF (sVEGF). Results: The positive rates of p53 and HIF-1α (diffuse, deep, intravascular pattern) were 38.6% and 15.8%, respectively. The VEGF overexpression rate was 57.9%. p53 and HIF-1α were correlated positively with the depth of invasion (P = 0.015, P = 0.001, respectively). Preoperative sVEGF and p53 levels were correlated significantly with lymph node involvement (P = 0.010, P = 0.040, respectively). VEGF overexpression was more frequently observed in the old age group (≥ 60 years old) and the intestinal type (P = 0.013, P = 0.014, respectively). However, correlations between preoperative sVEGF level and tissue HIF-1α, VEGF, and p53 were not observed. The median follow-up duration after operation was 24.5 months. HIF-1α was observed to be a poor prognostic factor of disease recurrence or progression (P = 0.002). Conclusion: p53, HIF-1α and preoperative sVEGF might be markers of depth of invasion or lymph node involvement. HIF-1α expression was a poor prognostic factor of disease recurrence or progression in patients with gastric cancers.